652 related articles for article (PubMed ID: 36275664)
41. Identification and Development of an Age-Related Classification and Signature to Predict Prognosis and Immune Landscape in Osteosarcoma.
Hong J; Wang X; Yu L; Li J; Hu H; Mao W
J Oncol; 2022; 2022():5040458. PubMed ID: 36276293
[TBL] [Abstract][Full Text] [Related]
42. A novel immune cell signature for predicting osteosarcoma prognosis and guiding therapy.
Pan R; Pan F; Zeng Z; Lei S; Yang Y; Yang Y; Hu C; Chen H; Tian X
Front Immunol; 2022; 13():1017120. PubMed ID: 36189307
[TBL] [Abstract][Full Text] [Related]
43. A Risk Model Based on Immune-Related Genes Predicts Prognosis and Characterizes the Immune Landscape in Esophageal Cancer.
Xie Y; Fu R; Xiao Z; Li G
Pathol Oncol Res; 2022; 28():1610030. PubMed ID: 35356506
[TBL] [Abstract][Full Text] [Related]
44. Comprehensive analysis of a glycolysis and cholesterol synthesis-related genes signature for predicting prognosis and immune landscape in osteosarcoma.
Xu F; Yan J; Peng Z; Liu J; Li Z
Front Immunol; 2022; 13():1096009. PubMed ID: 36618348
[TBL] [Abstract][Full Text] [Related]
45. N6-methyladenosine Modification-Related Long Non-Coding RNAs are Potential Biomarkers for Predicting the Prognosis of Patients With Osteosarcoma.
Yang K; Wang F; Li K; Peng G; Yang H; Xu H; Xiang Y; Sun H
Technol Cancer Res Treat; 2022; 21():15330338221085354. PubMed ID: 35422168
[No Abstract] [Full Text] [Related]
46. CRISPR-Cas9 screening identified lethal genes enriched in necroptosis pathway and of prognosis significance in osteosarcoma.
Cheng L; Xiong W; Li S; Wang G; Zhou J; Li H
J Gene Med; 2023 Dec; 25(12):e3563. PubMed ID: 37421290
[TBL] [Abstract][Full Text] [Related]
47. Four differentially expressed genes can predict prognosis and microenvironment immune infiltration in lung cancer: a study based on data from the GEO.
Wen S; Peng W; Chen Y; Du X; Xia J; Shen B; Zhou G
BMC Cancer; 2022 Feb; 22(1):193. PubMed ID: 35184748
[TBL] [Abstract][Full Text] [Related]
48. Transcriptomic correlates of cell cycle checkpoints with distinct prognosis, molecular characteristics, immunological regulation, and therapeutic response in colorectal adenocarcinoma.
Wang H; Wang W; Wang Z; Li X
Front Immunol; 2023; 14():1291859. PubMed ID: 38143740
[TBL] [Abstract][Full Text] [Related]
49. Construction of an ER stress-related prognostic signature for predicting prognosis and screening the effective anti-tumor drug in osteosarcoma.
Chen W; Liao Y; Sun P; Tu J; Zou Y; Fang J; Chen Z; Li H; Chen J; Peng Y; Wen L; Xie X
J Transl Med; 2024 Jan; 22(1):66. PubMed ID: 38229155
[TBL] [Abstract][Full Text] [Related]
50. Construction and validation model of necroptosis-related gene signature associates with immunity for osteosarcoma patients.
Hua L; Lei P; Hu Y
Sci Rep; 2022 Sep; 12(1):15893. PubMed ID: 36151259
[TBL] [Abstract][Full Text] [Related]
51. Dissecting the effect of sphingolipid metabolism gene in progression and microenvironment of osteosarcoma to develop a prognostic signature.
Zhong Y; Zhang Y; Wei S; Chen J; Zhong C; Cai W; Jin W; Peng H
Front Endocrinol (Lausanne); 2022; 13():1030655. PubMed ID: 36313783
[TBL] [Abstract][Full Text] [Related]
52. Immunogenic cell death related mRNAs associated signature to predict immunotherapeutic response in osteosarcoma.
Han S; Wang Q; Shen M; Zhang X; Wang J
Heliyon; 2024 Mar; 10(6):e27630. PubMed ID: 38515694
[TBL] [Abstract][Full Text] [Related]
53. C-C Motif Chemokine Ligand 5 (CCL5): A Potential Biomarker and Immunotherapy Target for Osteosarcoma.
Zheng H; Wang Y; Li F
Curr Cancer Drug Targets; 2024; 24(3):308-318. PubMed ID: 37581517
[TBL] [Abstract][Full Text] [Related]
54. Development of a prognostic model to predict BLCA based on anoikis-related gene signature: preliminary findings.
Zhu S; Zhao Q; Fan Y; Tang C
BMC Urol; 2023 Dec; 23(1):199. PubMed ID: 38049825
[TBL] [Abstract][Full Text] [Related]
55. Developing a prognosis and chemotherapy evaluating model for colon adenocarcinoma based on mitotic catastrophe-related genes.
Liu Y; Zhao Y; Zhang S; Rong S; He S; Hua L; Wang X; Chen H
Sci Rep; 2024 Jan; 14(1):1655. PubMed ID: 38238555
[TBL] [Abstract][Full Text] [Related]
56. Identification and validation of a novel senescence-related biomarker for thyroid cancer to predict the prognosis and immunotherapy.
Hong K; Cen K; Chen Q; Dai Y; Mai Y; Guo Y
Front Immunol; 2023; 14():1128390. PubMed ID: 36761753
[TBL] [Abstract][Full Text] [Related]
57. Molecular map of disulfidptosis-related genes in lung adenocarcinoma: the perspective toward immune microenvironment and prognosis.
Zhao F; Su L; Wang X; Luan J; Zhang X; Li Y; Li S; Hu L
Clin Epigenetics; 2024 Feb; 16(1):26. PubMed ID: 38342890
[TBL] [Abstract][Full Text] [Related]
58. Senescence gene expression in clear cell renal cell carcinoma: Role of tumor immune microenvironment and senescence-associated survival prediction.
Wu Y; Li X
Medicine (Baltimore); 2023 Oct; 102(40):e35222. PubMed ID: 37800815
[TBL] [Abstract][Full Text] [Related]
59. Identification and prognostic evaluation of differentially expressed long noncoding RNAs associated with immune infiltration in osteosarcoma.
Wang B; Wang X; Du X; Gao S; Liang B; Yao W
Heliyon; 2024 Mar; 10(5):e27023. PubMed ID: 38463807
[TBL] [Abstract][Full Text] [Related]
60. Development and validation of apoptosis-related signature and molecular subtype to improve prognosis prediction in osteosarcoma patients.
Hong J; Li Q; Wang X; Li J; Ding W; Hu H; He L
J Clin Lab Anal; 2022 Jul; 36(7):e24501. PubMed ID: 35576501
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
